Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christopher D Payne

Showing results (21-30 of 40) with videos related to

Pageof 4
Sort By:
Journal of Clinical Pharmacology|February 28, 2008
Effects of the proton pump inhibitor lansoprazole on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrelDavid S Small, Nagy A Farid, Christopher D Payne, et al.
Clinical Pharmacology and Therapeutics|June 27, 2025
Comparison of Regression and Categorical Analysis for Pharmacokinetic Data From Renal Impairment StudiesGerald Chun-To So, Ying Grace Li, Stephen D Hall, et al.
Platelets|June 24, 2008
Switching directly to prasugrel from clopidogrel results in greater inhibition of platelet aggregation in aspirin-treated subjectsChristopher D Payne, Ying G Li, John T Brandt, et al.
Thrombosis and Haemostasis|February 19, 2008
The use of the VerifyNow P2Y12 point-of-care device to monitor platelet function across a range of P2Y12 inhibition levels following prasugrel and clopidogrel administrationJoseph A Jakubowski, Christopher D Payne, Ying G Li, et al.
Thrombosis and Haemostasis|January 25, 2008
A comparison of the antiplatelet effects of prasugrel and high-dose clopidogrel as assessed by VASP-phosphorylation and light transmission aggregometryJoseph A Jakubowski, Christopher D Payne, Ying G Li, et al.
Journal of Clinical Pharmacology|April 23, 2010
Integrated analysis of pharmacokinetic data across multiple clinical pharmacology studies of prasugrel, a new thienopyridine antiplatelet agentDavid S Small, Ying G Li, C Steven Ernest, et al.
American Heart Journal|December 19, 2006
A comparison of prasugrel and clopidogrel loading doses on platelet function: magnitude of platelet inhibition is related to active metabolite formationJohn T Brandt, Christopher D Payne, Stephen D Wiviott, et al.
The American Journal of Cardiology|July 17, 2007
Comparison of speed of onset of platelet inhibition after loading doses of clopidogrel versus prasugrel in healthy volunteers and correlation with responder statusGovinda J Weerakkody, Joseph A Jakubowski, John T Brandt, et al.
Drugs & Aging|September 5, 2009
Effect of age on the pharmacokinetics and pharmacodynamics of prasugrel during multiple dosing: an open-label, single-sequence, clinical trialDavid S Small, Rebecca E Wrishko, C Steven Ernest, et al.
Thrombosis Research|December 26, 2013
A phase 1 study of prasugrel in patients with sickle cell disease: effects on biomarkers of platelet activation and coagulationJoseph A Jakubowski, Chunmei Zhou, Stipo Jurcevic, et al.
Pageof 4

Showing results (21-30 of 40) with videos related to

Sort By:
Pageof 4
Journal of Clinical Pharmacology|February 28, 2008
Effects of the proton pump inhibitor lansoprazole on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrelDavid S Small, Nagy A Farid, Christopher D Payne, et al.
Clinical Pharmacology and Therapeutics|June 27, 2025
Comparison of Regression and Categorical Analysis for Pharmacokinetic Data From Renal Impairment StudiesGerald Chun-To So, Ying Grace Li, Stephen D Hall, et al.
Platelets|June 24, 2008
Switching directly to prasugrel from clopidogrel results in greater inhibition of platelet aggregation in aspirin-treated subjectsChristopher D Payne, Ying G Li, John T Brandt, et al.
Thrombosis and Haemostasis|February 19, 2008
The use of the VerifyNow P2Y12 point-of-care device to monitor platelet function across a range of P2Y12 inhibition levels following prasugrel and clopidogrel administrationJoseph A Jakubowski, Christopher D Payne, Ying G Li, et al.
Thrombosis and Haemostasis|January 25, 2008
A comparison of the antiplatelet effects of prasugrel and high-dose clopidogrel as assessed by VASP-phosphorylation and light transmission aggregometryJoseph A Jakubowski, Christopher D Payne, Ying G Li, et al.
Journal of Clinical Pharmacology|April 23, 2010
Integrated analysis of pharmacokinetic data across multiple clinical pharmacology studies of prasugrel, a new thienopyridine antiplatelet agentDavid S Small, Ying G Li, C Steven Ernest, et al.
American Heart Journal|December 19, 2006
A comparison of prasugrel and clopidogrel loading doses on platelet function: magnitude of platelet inhibition is related to active metabolite formationJohn T Brandt, Christopher D Payne, Stephen D Wiviott, et al.
The American Journal of Cardiology|July 17, 2007
Comparison of speed of onset of platelet inhibition after loading doses of clopidogrel versus prasugrel in healthy volunteers and correlation with responder statusGovinda J Weerakkody, Joseph A Jakubowski, John T Brandt, et al.
Drugs & Aging|September 5, 2009
Effect of age on the pharmacokinetics and pharmacodynamics of prasugrel during multiple dosing: an open-label, single-sequence, clinical trialDavid S Small, Rebecca E Wrishko, C Steven Ernest, et al.
Thrombosis Research|December 26, 2013
A phase 1 study of prasugrel in patients with sickle cell disease: effects on biomarkers of platelet activation and coagulationJoseph A Jakubowski, Chunmei Zhou, Stipo Jurcevic, et al.
Pageof 4